{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:18:41Z","timestamp":1790651921621,"version":"4.1.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010607","name":"Universit\u00e0 degli Studi di Perugia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010607","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The role of B cells in the pathophysiology of multiple sclerosis (MS) extends beyond antibody synthesis, also involving the modulation of T lymphocytes and myeloid cells. B-cell activation within the Central Nervous System is associated with the release of various antibodies, cytokines, and chemokines, measurable in biofluids, thereby serving as biomarkers of the immune processes responsible for MS. To this purpose, a biomarker-based characterization of the disease through the combination of well-established markers, e.g., immunoglobulin (Ig) G index, IgG oligoclonal bands, Ig free light chains, with new promising markers, namely chemokine (C\u2013X\u2013C motif) ligand 13, and B-cell activating factor\/A proliferation-inducing ligand, might represent a significant improvement in the management of people with MS.<\/jats:p>","DOI":"10.1007\/s00415-025-12907-6","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T03:20:29Z","timestamp":1739762429000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["CSF biomarkers of B-cell activation in multiple sclerosis: a clinical perspective"],"prefix":"10.1007","volume":"272","author":[{"given":"Elena","family":"Di Sabatino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gaetani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Emiliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucilla","family":"Parnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2645-7477","authenticated-orcid":false,"given":"Massimiliano","family":"Di Filippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"12907_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378:169\u2013180. https:\/\/doi.org\/10.1056\/NEJMra1401483","journal-title":"N Engl J Med"},{"key":"12907_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F et al (2018) Multiple sclerosis. Nat Rev Dis Primers 4:43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nat Rev Dis Primers"},{"key":"12907_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.100977","volume":"44","author":"E Portaccio","year":"2024","unstructured":"Portaccio E, Magyari M, Havrdova EK et al (2024) Multiple sclerosis: emerging epidemiological trends and redefining the clinical course. Lancet Reg Health Europe 44:100977. https:\/\/doi.org\/10.1016\/j.lanepe.2024.100977","journal-title":"Lancet Reg Health Europe"},{"key":"12907_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01473-3","author":"D Jakimovski","year":"2023","unstructured":"Jakimovski D, Bittner S, Zivadinov R et al (2023) Multiple sclerosis. The Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(23)01473-3","journal-title":"The Lancet"},{"key":"12907_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545\u2013558. https:\/\/doi.org\/10.1038\/nri3871","journal-title":"Nat Rev Immunol"},{"key":"12907_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S1474-4422(23)00281-8","volume":"22","author":"C Lebrun-Frenay","year":"2023","unstructured":"Lebrun-Frenay C, Kantarci O, Siva A et al (2023) Radiologically isolated syndrome. Lancet Neurol 22:1075\u20131086. https:\/\/doi.org\/10.1016\/S1474-4422(23)00281-8","journal-title":"Lancet Neurol"},{"key":"12907_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA et al (2014) Defining the clinical course of multiple sclerosis. Neurology 83:278\u2013286. https:\/\/doi.org\/10.1212\/WNL.0000000000000560","journal-title":"Neurology"},{"key":"12907_CR8","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1093\/brain\/awac016","volume":"145","author":"FD Lublin","year":"2022","unstructured":"Lublin FD, H\u00e4ring DA, Ganjgahi H et al (2022) How patients with multiple sclerosis acquire disability. Brain 145:3147\u20133161. https:\/\/doi.org\/10.1093\/brain\/awac016","journal-title":"Brain"},{"key":"12907_CR9","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173. https:\/\/doi.org\/10.1016\/S1474-4422(17)30470-2","journal-title":"Lancet Neurol"},{"key":"12907_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/WCO.0000000000000561","volume":"31","author":"G Giovannoni","year":"2018","unstructured":"Giovannoni G (2018) Disease-modifying treatments for early and advanced multiple sclerosis. Curr Opin Neurol 31:233\u2013243. https:\/\/doi.org\/10.1097\/WCO.0000000000000561","journal-title":"Curr Opin Neurol"},{"key":"12907_CR11","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.tips.2020.09.011","volume":"41","author":"L Gaetani","year":"2020","unstructured":"Gaetani L, Paolini Paoletti F, Bellomo G et al (2020) CSF and blood biomarkers in neuroinflammatory and neurodegenerative diseases: implications for treatment. Trends Pharmacol Sci 41:1023\u20131037. https:\/\/doi.org\/10.1016\/j.tips.2020.09.011","journal-title":"Trends Pharmacol Sci"},{"key":"12907_CR12","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","volume":"19","author":"R Li","year":"2018","unstructured":"Li R, Patterson KR, Bar-Or A (2018) Reassessing B cell contributions in multiple sclerosis. Nat Immunol 19:696\u2013707. https:\/\/doi.org\/10.1038\/s41590-018-0135-x","journal-title":"Nat Immunol"},{"key":"12907_CR13","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni MT, Mattoscio M, Magliozzi R et al (2021) B cells in multiple sclerosis: from targeted depletion to immune reconstitution therapies. Nat Rev Neurol 17:399\u2013414. https:\/\/doi.org\/10.1038\/s41582-021-00498-5","journal-title":"Nat Rev Neurol"},{"key":"12907_CR14","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.4049\/jimmunol.176.6.3498","volume":"176","author":"A Crawford","year":"2006","unstructured":"Crawford A, MacLeod M, Schumacher T et al (2006) Primary T cell expansion and differentiation in vivo requires antigen presentation by B cells. J Immunol 176:3498\u20133506. https:\/\/doi.org\/10.4049\/jimmunol.176.6.3498","journal-title":"J Immunol"},{"key":"12907_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/nri2729","volume":"10","author":"FE Lund","year":"2010","unstructured":"Lund FE, Randall TD (2010) Effector and regulatory B cells: modulators of CD4+ T cell immunity. Nat Rev Immunol 10:236\u2013247. https:\/\/doi.org\/10.1038\/nri2729","journal-title":"Nat Rev Immunol"},{"key":"12907_CR16","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1002\/eji.200838201","volume":"38","author":"S Shah","year":"2008","unstructured":"Shah S, Qiao L (2008) Resting B cells expand a CD4 + CD25 + Foxp3 + Treg population via TGF-\u03b23. Eur J Immunol 38:2488\u20132498. https:\/\/doi.org\/10.1002\/eji.200838201","journal-title":"Eur J Immunol"},{"key":"12907_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nri2315","volume":"8","author":"S Fillatreau","year":"2008","unstructured":"Fillatreau S, Gray D, Anderton SM (2008) Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 8:391\u2013397. https:\/\/doi.org\/10.1038\/nri2315","journal-title":"Nat Rev Immunol"},{"key":"12907_CR18","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1600-065X.2008.00661.x","volume":"224","author":"J Bouaziz","year":"2008","unstructured":"Bouaziz J, Yanaba K, Tedder TF (2008) Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev 224:201\u2013214. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00661.x","journal-title":"Immunol Rev"},{"key":"12907_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::aid-ana3>3.0.co;2-q","volume":"47","author":"C Lucchinetti","year":"2000","unstructured":"Lucchinetti C, Br\u00fcck W, Parisi J et al (2000) Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 47:707\u2013717. https:\/\/doi.org\/10.1002\/1531-8249(200006)47:6%3c707::aid-ana3%3e3.0.co;2-q","journal-title":"Ann Neurol"},{"key":"12907_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/ana.25927","volume":"89","author":"G Comi","year":"2021","unstructured":"Comi G, Bar-Or A, Lassmann H et al (2021) Role of B cells in multiple sclerosis and related disorders. Ann Neurol 89:13\u201323. https:\/\/doi.org\/10.1002\/ana.25927","journal-title":"Ann Neurol"},{"key":"12907_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2006","unstructured":"Magliozzi R, Howell O, Vora A et al (2006) Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130:1089\u20131104. https:\/\/doi.org\/10.1093\/brain\/awm038","journal-title":"Brain"},{"key":"12907_CR22","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1093\/brain\/awr182","volume":"134","author":"OW Howell","year":"2011","unstructured":"Howell OW, Reeves CA, Nicholas R et al (2011) Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 134:2755\u20132771. https:\/\/doi.org\/10.1093\/brain\/awr182","journal-title":"Brain"},{"key":"12907_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jneuroim.2006.07.006","volume":"180","author":"H Link","year":"2006","unstructured":"Link H, Huang Y-M (2006) Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol 180:17\u201328. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.07.006","journal-title":"J Neuroimmunol"},{"key":"12907_CR24","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","volume":"8","author":"M Krumbholz","year":"2012","unstructured":"Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8:613\u2013623. https:\/\/doi.org\/10.1038\/nrneurol.2012.203","journal-title":"Nat Rev Neurol"},{"key":"12907_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz TV, Brewer RC, Ho PP et al (2022) Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603:321\u2013327. https:\/\/doi.org\/10.1038\/s41586-022-04432-7","journal-title":"Nature"},{"key":"12907_CR26","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/5532","volume":"5","author":"CP Genain","year":"1999","unstructured":"Genain CP, Cannella B, Hauser SL, Raine CS (1999) Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med 5:170\u2013175. https:\/\/doi.org\/10.1038\/5532","journal-title":"Nat Med"},{"key":"12907_CR27","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.1073\/pnas.1522730113","volume":"113","author":"SM Br\u00e4ndle","year":"2016","unstructured":"Br\u00e4ndle SM, Obermeier B, Senel M et al (2016) Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci 113:7864\u20137869. https:\/\/doi.org\/10.1073\/pnas.1522730113","journal-title":"Proc Natl Acad Sci"},{"key":"12907_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s00415-023-12081-7","volume":"271","author":"PGE Kennedy","year":"2024","unstructured":"Kennedy PGE, George W, Yu X (2024) The elusive nature of the oligoclonal bands in multiple sclerosis. J Neurol 271:116\u2013124. https:\/\/doi.org\/10.1007\/s00415-023-12081-7","journal-title":"J Neurol"},{"key":"12907_CR29","doi-asserted-by":"publisher","DOI":"10.1172\/JCI162731","author":"GP Owens","year":"2023","unstructured":"Owens GP, Fellin TJ, Matschulat A et al (2023) Pathogenic myelin-specific antibodies in multiple sclerosis target conformational proteolipid protein 1\u2013anchored membrane domains. J Clin Investig. https:\/\/doi.org\/10.1172\/JCI162731","journal-title":"J Clin Investig"},{"key":"12907_CR30","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/ana.25197","volume":"83","author":"R Magliozzi","year":"2018","unstructured":"Magliozzi R, Howell OW, Nicholas R et al (2018) Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. Ann Neurol 83:739\u2013755. https:\/\/doi.org\/10.1002\/ana.25197","journal-title":"Ann Neurol"},{"key":"12907_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00565","author":"K Blauth","year":"2015","unstructured":"Blauth K, Owens GP, Bennett JL (2015) The ins and outs of B cells in multiple sclerosis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2015.00565","journal-title":"Front Immunol"},{"key":"12907_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008930","author":"A Palanichamy","year":"2014","unstructured":"Palanichamy A, Apeltsin L, Kuo TC et al (2014) Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.3008930","journal-title":"Sci Transl Med"},{"key":"12907_CR33","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/ana.24088","volume":"75","author":"J Bankoti","year":"2014","unstructured":"Bankoti J, Apeltsin L, Hauser SL et al (2014) In multiple sclerosis, oligoclonal bands connect to peripheral B-cell responses. Ann Neurol 75:266\u2013276. https:\/\/doi.org\/10.1002\/ana.24088","journal-title":"Ann Neurol"},{"key":"12907_CR34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PAJ, Arnold D et al (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395\u2013400. https:\/\/doi.org\/10.1002\/ana.21363","journal-title":"Ann Neurol"},{"key":"12907_CR35","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"TA Barr","year":"2012","unstructured":"Barr TA, Shen P, Brown S et al (2012) B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6\u2013producing B cells. J Exp Med 209:1001\u20131010. https:\/\/doi.org\/10.1084\/jem.20111675","journal-title":"J Exp Med"},{"key":"12907_CR36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aab4176","author":"R Li","year":"2015","unstructured":"Li R, Rezk A, Miyazaki Y et al (2015) Proinflammatory GM-CSF\u2013producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aab4176","journal-title":"Sci Transl Med"},{"key":"12907_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jneuroim.2017.05.004","volume":"309","author":"RP Lisak","year":"2017","unstructured":"Lisak RP, Nedelkoska L, Benjamins JA et al (2017) B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro. J Neuroimmunol 309:88\u201399. https:\/\/doi.org\/10.1016\/j.jneuroim.2017.05.004","journal-title":"J Neuroimmunol"},{"key":"12907_CR38","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1084\/jem.20130699","volume":"210","author":"N Molnarfi","year":"2013","unstructured":"Molnarfi N, Schulze-Topphoff U, Weber MS et al (2013) MHC class II\u2013dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med 210:2921\u20132937. https:\/\/doi.org\/10.1084\/jem.20130699","journal-title":"J Exp Med"},{"key":"12907_CR39","doi-asserted-by":"publisher","DOI":"10.1172\/JCI36030","author":"T Matsushita","year":"2008","unstructured":"Matsushita T, Yanaba K, Bouaziz J-D et al (2008) Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Investig. https:\/\/doi.org\/10.1172\/JCI36030","journal-title":"J Clin Investig"},{"key":"12907_CR40","doi-asserted-by":"publisher","first-page":"12598","DOI":"10.1523\/JNEUROSCI.1994-16.2016","volume":"36","author":"A Pennati","year":"2016","unstructured":"Pennati A, Ng S, Wu Y et al (2016) Regulatory B cells induce formation of IL-10-expressing T cells in mice with autoimmune neuroinflammation. J Neurosci 36:12598\u201312610. https:\/\/doi.org\/10.1523\/JNEUROSCI.1994-16.2016","journal-title":"J Neurosci"},{"key":"12907_CR41","doi-asserted-by":"publisher","first-page":"5105","DOI":"10.1523\/JNEUROSCI.2840-19.2020","volume":"40","author":"A Pennati","year":"2020","unstructured":"Pennati A, Nylen EA, Duncan ID, Galipeau J (2020) Regulatory B cells normalize CNS myeloid cell content in a mouse model of multiple sclerosis and promote oligodendrogenesis and remyelination. J Neurosci 40:5105\u20135115. https:\/\/doi.org\/10.1523\/JNEUROSCI.2840-19.2020","journal-title":"J Neurosci"},{"key":"12907_CR42","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.3390\/brainsci11111444","volume":"11","author":"M Fonderico","year":"2021","unstructured":"Fonderico M, Portaccio E, Razzolini L et al (2021) Cerebrospinal fluid IgM and oligoclonal IgG bands in multiple sclerosis: a meta-analysis of prevalence and prognosis. Brain Sci 11:1444. https:\/\/doi.org\/10.3390\/brainsci11111444","journal-title":"Brain Sci"},{"key":"12907_CR43","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1038\/s41598-022-08099-y","volume":"12","author":"\u00da Mu\u00f1oz","year":"2022","unstructured":"Mu\u00f1oz \u00da, Sebal C, Escudero E et al (2022) High prevalence of intrathecal IgA synthesis in multiple sclerosis patients. Sci Rep 12:4247. https:\/\/doi.org\/10.1038\/s41598-022-08099-y","journal-title":"Sci Rep"},{"key":"12907_CR44","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/14737159.2017.1262260","volume":"17","author":"M Gastaldi","year":"2017","unstructured":"Gastaldi M, Zardini E, Franciotta D (2017) An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis. Expert Rev Mol Diagn 17:31\u201346. https:\/\/doi.org\/10.1080\/14737159.2017.1262260","journal-title":"Expert Rev Mol Diagn"},{"key":"12907_CR45","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/jnnp.57.8.897","volume":"57","author":"M Andersson","year":"1994","unstructured":"Andersson M, Alvarez-Cermeno J, Bernardi G et al (1994) Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J Neurol Neurosurg Psychiatry 57:897\u2013902. https:\/\/doi.org\/10.1136\/jnnp.57.8.897","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12907_CR46","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.6.865","author":"MS Freedman","year":"2005","unstructured":"Freedman MS, Thompson EJ, Deisenhammer F et al (2005) Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis. Arch Neurol. https:\/\/doi.org\/10.1001\/archneur.62.6.865","journal-title":"Arch Neurol"},{"key":"12907_CR47","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cca.2011.03.007","volume":"412","author":"T Nakano","year":"2011","unstructured":"Nakano T, Matsui M, Inoue I et al (2011) Free immunoglobulin light chain: Its biology and implications in diseases. Clin Chim Acta 412:843\u2013849. https:\/\/doi.org\/10.1016\/j.cca.2011.03.007","journal-title":"Clin Chim Acta"},{"key":"12907_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577108","volume":"339","author":"L Gaetani","year":"2020","unstructured":"Gaetani L, Di Carlo M, Brachelente G et al (2020) Cerebrospinal fluid free light chains compared to oligoclonal bands as biomarkers in multiple sclerosis. J Neuroimmunol 339:577108. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577108","journal-title":"J Neuroimmunol"},{"key":"12907_CR49","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1177\/1352458518770088","volume":"25","author":"N McNicholas","year":"2019","unstructured":"McNicholas N, Lockhart A, Yap SM et al (2019) New versus old: Implications of evolving diagnostic criteria for relapsing\u2013remitting multiple sclerosis. Mult Scler J 25:867\u2013870. https:\/\/doi.org\/10.1177\/1352458518770088","journal-title":"Mult Scler J"},{"key":"12907_CR50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jneuroim.2009.10.005","volume":"218","author":"H-C von B\u00fcdingen","year":"2010","unstructured":"von B\u00fcdingen H-C, Gulati M, Kuenzle S et al (2010) Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce \u201coligoclonal bands.\u201d J Neuroimmunol 218:134\u2013139. https:\/\/doi.org\/10.1016\/j.jneuroim.2009.10.005","journal-title":"J Neuroimmunol"},{"key":"12907_CR51","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI3568","volume":"102","author":"Y Qin","year":"1998","unstructured":"Qin Y, Duquette P, Zhang Y et al (1998) Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Investig 102:1045\u20131050. https:\/\/doi.org\/10.1172\/JCI3568","journal-title":"J Clin Investig"},{"key":"12907_CR52","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nm1714","volume":"14","author":"B Obermeier","year":"2008","unstructured":"Obermeier B, Mentele R, Malotka J et al (2008) Matching of oligoclonal immunoglobulin transcriptomes and proteomes of cerebrospinal fluid in multiple sclerosis. Nat Med 14:688\u2013693. https:\/\/doi.org\/10.1038\/nm1714","journal-title":"Nat Med"},{"key":"12907_CR53","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1474-4422(08)70192-3","volume":"7","author":"D Franciotta","year":"2008","unstructured":"Franciotta D, Salvetti M, Lolli F et al (2008) B cells and multiple sclerosis. Lancet Neurol 7:852\u2013858. https:\/\/doi.org\/10.1016\/S1474-4422(08)70192-3","journal-title":"Lancet Neurol"},{"key":"12907_CR54","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/jnnp-2012-304695","volume":"84","author":"R Dobson","year":"2013","unstructured":"Dobson R, Ramagopalan S, Davis A, Giovannoni G (2013) Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: a meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 84:909\u2013914. https:\/\/doi.org\/10.1136\/jnnp-2012-304695","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12907_CR55","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1007\/s00415-018-9048-8","volume":"265","author":"L Gaetani","year":"2018","unstructured":"Gaetani L, Prosperini L, Mancini A et al (2018) 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes. J Neurol 265:2684\u20132687. https:\/\/doi.org\/10.1007\/s00415-018-9048-8","journal-title":"J Neurol"},{"key":"12907_CR56","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1093\/brain\/awv105","volume":"138","author":"M Tintore","year":"2015","unstructured":"Tintore M, Rovira \u00c0, R\u00edo J et al (2015) Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain 138:1863\u20131874. https:\/\/doi.org\/10.1093\/brain\/awv105","journal-title":"Brain"},{"key":"12907_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2013.06.014","volume":"262","author":"A Petzold","year":"2013","unstructured":"Petzold A (2013) Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J Neuroimmunol 262:1\u201310. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.06.014","journal-title":"J Neuroimmunol"},{"key":"12907_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/ijms25010139","volume":"25","author":"L Gaetani","year":"2023","unstructured":"Gaetani L, Bellomo G, Di Sabatino E et al (2023) The immune signature of CSF in multiple sclerosis with and without oligoclonal bands: a machine learning approach to proximity extension assay analysis. Int J Mol Sci 25:139. https:\/\/doi.org\/10.3390\/ijms25010139","journal-title":"Int J Mol Sci"},{"key":"12907_CR59","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/jnnp.43.2.102","volume":"43","author":"L Stendahl-Brodin","year":"1980","unstructured":"Stendahl-Brodin L, Link H (1980) Relation between benign course of multiple sclerosis and low-grade humoral immune response in cerebrospinal fluid. J Neurol Neurosurg Psychiatry 43:102\u2013105. https:\/\/doi.org\/10.1136\/jnnp.43.2.102","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12907_CR60","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/jnnp.2008.150896","volume":"80","author":"FG Joseph","year":"2009","unstructured":"Joseph FG, Hirst CL, Pickersgill TP et al (2009) CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 80:292\u2013296. https:\/\/doi.org\/10.1136\/jnnp.2008.150896","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"12907_CR61","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1093\/brain\/awy021","volume":"141","author":"C Matute-Blanch","year":"2018","unstructured":"Matute-Blanch C, Villar LM, \u00c1lvarez-Cerme\u00f1o JC et al (2018) Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome. Brain 141:1085\u20131093. https:\/\/doi.org\/10.1093\/brain\/awy021","journal-title":"Brain"},{"key":"12907_CR62","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","volume":"80","author":"C Tur","year":"2023","unstructured":"Tur C, Carbonell-Mirabent P, Cobo-Calvo \u00c1 et al (2023) Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol 80:151. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4655","journal-title":"JAMA Neurol"},{"key":"12907_CR63","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s10072-015-2303-1","volume":"36","author":"M Anagnostouli","year":"2015","unstructured":"Anagnostouli M, Christidi F, Zalonis I et al (2015) Clinical and cognitive implications of cerebrospinal fluid oligoclonal bands in multiple sclerosis patients. Neurol Sci 36:2053\u20132060. https:\/\/doi.org\/10.1007\/s10072-015-2303-1","journal-title":"Neurol Sci"},{"key":"12907_CR64","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12974-017-0812-y","volume":"14","author":"G Farina","year":"2017","unstructured":"Farina G, Magliozzi R, Pitteri M et al (2017) Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. J Neuroinflammation 14:40. https:\/\/doi.org\/10.1186\/s12974-017-0812-y","journal-title":"J Neuroinflammation"},{"key":"12907_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/1673-5374.286949","volume":"16","author":"L Gaetani","year":"2021","unstructured":"Gaetani L, Salvadori N, Chipi E et al (2021) Cognitive impairment in multiple sclerosis: lessons from cerebrospinal fluid biomarkers. Neural Regen Res 16:36. https:\/\/doi.org\/10.4103\/1673-5374.286949","journal-title":"Neural Regen Res"},{"key":"12907_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jns.2008.12.029","volume":"279","author":"S Siritho","year":"2009","unstructured":"Siritho S, Freedman MS (2009) The prognostic significance of cerebrospinal fluid in multiple sclerosis. J Neurol Sci 279:21\u201325. https:\/\/doi.org\/10.1016\/j.jns.2008.12.029","journal-title":"J Neurol Sci"},{"key":"12907_CR67","doi-asserted-by":"publisher","first-page":"205521731990129","DOI":"10.1177\/2055217319901291","volume":"6","author":"CS Simonsen","year":"2020","unstructured":"Simonsen CS, Flemmen H\u00d8, Lauritzen T et al (2020) The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis. Mult Scler J Exp Transl Clin 6:205521731990129. https:\/\/doi.org\/10.1177\/2055217319901291","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12907_CR68","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1034\/j.1600-0404.2002.1o009.x","volume":"105","author":"G Izquierdo","year":"2002","unstructured":"Izquierdo G, Angulo S, Garcia-Moreno JM et al (2002) Intrathecal IgG synthesis: marker of progression in multiple sclerosis patients. Acta Neurol Scand 105:158\u2013163. https:\/\/doi.org\/10.1034\/j.1600-0404.2002.1o009.x","journal-title":"Acta Neurol Scand"},{"key":"12907_CR69","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jon.12435","volume":"27","author":"N Seraji-Bozorgzad","year":"2017","unstructured":"Seraji-Bozorgzad N, Khan O, Cree BAC et al (2017) Cerebral gray matter atrophy is associated with the CSF IgG index in African American with multiple sclerosis. J Neuroimaging 27:476\u2013480. https:\/\/doi.org\/10.1111\/jon.12435","journal-title":"J Neuroimaging"},{"key":"12907_CR70","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001047","author":"E Monreal","year":"2021","unstructured":"Monreal E, Sainz de la Maza S, Costa-Frossard L et al (2021) Predicting aggressive multiple sclerosis with intrathecal IgM synthesis among patients with a clinically isolated syndrome. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000001047","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12907_CR71","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1093\/brain\/awu205","volume":"137","author":"E Beltr\u00e1n","year":"2014","unstructured":"Beltr\u00e1n E, Obermeier B, Moser M et al (2014) Intrathecal somatic hypermutation of IgM in multiple sclerosis and neuroinflammation. Brain 137:2703\u20132714. https:\/\/doi.org\/10.1093\/brain\/awu205","journal-title":"Brain"},{"key":"12907_CR72","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1084\/jem.163.1.41","volume":"163","author":"MJ Walsh","year":"1986","unstructured":"Walsh MJ, Tourtellotte WW (1986) Temporal invariance and clonal uniformity of brain and cerebrospinal IgG, IgA, and IgM in multiple sclerosis. J Exp Med 163:41\u201353. https:\/\/doi.org\/10.1084\/jem.163.1.41","journal-title":"J Exp Med"},{"key":"12907_CR73","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1750-3639.1996.tb00854.x","volume":"6","author":"CF Lucchinetti","year":"1996","unstructured":"Lucchinetti CF, Br\u00fcck W, Rodriguez M, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity in pathogenesis. Brain Pathol 6:259\u2013274. https:\/\/doi.org\/10.1111\/j.1750-3639.1996.tb00854.x","journal-title":"Brain Pathol"},{"key":"12907_CR74","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1007\/s10571-021-01059-6","volume":"42","author":"U Mu\u00f1oz","year":"2022","unstructured":"Mu\u00f1oz U, Sebal C, Escudero E et al (2022) Main role of antibodies in demyelination and axonal damage in multiple sclerosis. Cell Mol Neurobiol 42:1809\u20131827. https:\/\/doi.org\/10.1007\/s10571-021-01059-6","journal-title":"Cell Mol Neurobiol"},{"key":"12907_CR75","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1023\/B:NEUR.0000010085.91976.a6","volume":"32","author":"J Rosenbluth","year":"2003","unstructured":"Rosenbluth J, Schiff R, Liang W-L, Dou W (2003) Antibody-mediated CNS demyelination II. Focal spinal cord lesions induced by implantation of an IgM antisulfatide-secreting hybridoma. J Neurocytol 32:265\u2013276. https:\/\/doi.org\/10.1023\/B:NEUR.0000010085.91976.a6","journal-title":"J Neurocytol"},{"key":"12907_CR76","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S0022-1759(01)00492-6","volume":"258","author":"LM Villar","year":"2001","unstructured":"Villar LM, Gonz\u00e1lez-Porqu\u00e9 P, Masju\u00e1n J et al (2001) A sensitive and reproducible method for the detection of oligoclonal IgM bands. J Immunol Methods 258:151\u2013155. https:\/\/doi.org\/10.1016\/S0022-1759(01)00492-6","journal-title":"J Immunol Methods"},{"key":"12907_CR77","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cca.2014.08.004","volume":"438","author":"M Espi\u00f1o","year":"2015","unstructured":"Espi\u00f1o M, Abraira V, Arroyo R et al (2015) Assessment of the reproducibility of oligoclonal IgM band detection for its application in daily clinical practice. Clin Chim Acta 438:67\u201369. https:\/\/doi.org\/10.1016\/j.cca.2014.08.004","journal-title":"Clin Chim Acta"},{"key":"12907_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112898","volume":"487","author":"CM Cabrera","year":"2020","unstructured":"Cabrera CM, Gosis A (2020) Semi-automated methodology for detection of IgM oligoclonal bands in cerebrospinal fluid and serum samples. J Immunol Methods 487:112898. https:\/\/doi.org\/10.1016\/j.jim.2020.112898","journal-title":"J Immunol Methods"},{"key":"12907_CR79","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-510X(94)90298-4","volume":"122","author":"H Reiber","year":"1994","unstructured":"Reiber H (1994) Flow rate of cerebrospinal fluid (CSF): a concept common to normal blood-CSF barrier function and to dysfunction in neurological diseases. J Neurol Sci 122:189\u2013203. https:\/\/doi.org\/10.1016\/0022-510X(94)90298-4","journal-title":"J Neurol Sci"},{"key":"12907_CR80","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1111\/ene.12924","volume":"23","author":"M Auer","year":"2016","unstructured":"Auer M, Hegen H, Zeileis A, Deisenhammer F (2016) Quantitation of intrathecal immunoglobulin synthesis: a new empirical formula. Eur J Neurol 23:713\u2013721. https:\/\/doi.org\/10.1111\/ene.12924","journal-title":"Eur J Neurol"},{"key":"12907_CR81","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1212\/WNL.59.4.555","volume":"59","author":"LM Villar","year":"2002","unstructured":"Villar LM, Masjuan J, Gonzalez-Porque P et al (2002) Intrathecal IgM synthesis predicts the onset of new relapses and a worse disease course in MS. Neurology 59:555\u2013559. https:\/\/doi.org\/10.1212\/WNL.59.4.555","journal-title":"Neurology"},{"key":"12907_CR82","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jneuroim.2013.01.011","volume":"257","author":"D Ferraro","year":"2013","unstructured":"Ferraro D, Simone AM, Bedin R et al (2013) Cerebrospinal fluid oligoclonal IgM bands predict early conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome. J Neuroimmunol 257:76\u201381. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.01.011","journal-title":"J Neuroimmunol"},{"key":"12907_CR83","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1212\/WNL.58.5.824","volume":"58","author":"LM Villar","year":"2002","unstructured":"Villar LM, Masjuan J, Gonzalez-Porque P et al (2002) Intrathecal IgM synthesis in neurologic diseases: relationship with disability in MS. Neurology 58:824\u2013826. https:\/\/doi.org\/10.1212\/WNL.58.5.824","journal-title":"Neurology"},{"key":"12907_CR84","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ana.10441","volume":"53","author":"LM Villar","year":"2003","unstructured":"Villar LM, Masjuan J, Gonz\u00e1lez-Porqu\u00e9 P et al (2003) Intrathecal IgM synthesis is a prognostic factor in multiple sclerosis. Ann Neurol 53:222\u2013226. https:\/\/doi.org\/10.1002\/ana.10441","journal-title":"Ann Neurol"},{"key":"12907_CR85","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ana.24190","volume":"76","author":"LM Villar","year":"2014","unstructured":"Villar LM, Casanova B, Ouamara N et al (2014) Immunoglobulin <scp>M<\/scp> oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. Ann Neurol 76:231\u2013240. https:\/\/doi.org\/10.1002\/ana.24190","journal-title":"Ann Neurol"},{"key":"12907_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.967953","author":"I Rosenstein","year":"2022","unstructured":"Rosenstein I, Rasch S, Axelsson M et al (2022) Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.967953","journal-title":"Front Immunol"},{"key":"12907_CR87","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/ana.26348","volume":"91","author":"J Oechtering","year":"2022","unstructured":"Oechtering J, Lincke T, Schaedelin S et al (2022) Intrathecal IgM synthesis is associated with spinal cord manifestation and neuronal injury in early MS. Ann Neurol 91:814\u2013820. https:\/\/doi.org\/10.1002\/ana.26348","journal-title":"Ann Neurol"},{"key":"12907_CR88","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1172\/JCI22833","volume":"115","author":"LM Villar","year":"2005","unstructured":"Villar LM, S\u00e1daba MC, Rold\u00e1n E et al (2005) Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Investig 115:187\u2013194. https:\/\/doi.org\/10.1172\/JCI22833","journal-title":"J Clin Investig"},{"key":"12907_CR89","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1177\/1352458507082046","volume":"14","author":"L Villar","year":"2008","unstructured":"Villar L, Garc\u00eda-Barrag\u00e1n N, Espi\u00f1o M et al (2008) Influence of oligoclonal IgM specificity in multiple sclerosis disease course. Mult Scler J 14:183\u2013187. https:\/\/doi.org\/10.1177\/1352458507082046","journal-title":"Mult Scler J"},{"key":"12907_CR90","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1177\/1352458508095729","volume":"14","author":"M Thangarajh","year":"2008","unstructured":"Thangarajh M, Gomez-Rial J, Hedstr\u00f6m A et al (2008) Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis. Mult Scler J 14:1208\u20131213. https:\/\/doi.org\/10.1177\/1352458508095729","journal-title":"Mult Scler J"},{"key":"12907_CR91","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00234-011-0841-7","volume":"54","author":"MJ Magraner","year":"2012","unstructured":"Magraner MJ, Bosca I, Sim\u00f3-Castell\u00f3 M et al (2012) Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes. Neuroradiology 54:5\u201312. https:\/\/doi.org\/10.1007\/s00234-011-0841-7","journal-title":"Neuroradiology"},{"key":"12907_CR92","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1111\/ene.12579","volume":"22","author":"LM Villar","year":"2015","unstructured":"Villar LM, Pic\u00f3n C, Costa-Frossard L et al (2015) Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis. Eur J Neurol 22:1169\u20131175. https:\/\/doi.org\/10.1111\/ene.12579","journal-title":"Eur J Neurol"},{"key":"12907_CR93","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jns.2015.11.030","volume":"360","author":"JC \u00c1lvarez-Cerme\u00f1o","year":"2016","unstructured":"\u00c1lvarez-Cerme\u00f1o JC, Mu\u00f1oz-Negrete FJ, Costa-Frossard L et al (2016) Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis. J Neurol Sci 360:41\u201344. https:\/\/doi.org\/10.1016\/j.jns.2015.11.030","journal-title":"J Neurol Sci"},{"key":"12907_CR94","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1515\/cclm-2017-0901","volume":"56","author":"KM Gurtner","year":"2018","unstructured":"Gurtner KM, Shosha E, Bryant SC et al (2018) CSF free light chain identification of demyelinating disease: comparison with oligoclonal banding and other CSF indexes. Clin Chem Lab Med (CCLM) 56:1071\u20131080. https:\/\/doi.org\/10.1515\/cclm-2017-0901","journal-title":"Clin Chem Lab Med (CCLM)"},{"key":"12907_CR95","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/jcp-2022-208354","volume":"76","author":"MA Abid","year":"2023","unstructured":"Abid MA, Ahmed S, Muneer S et al (2023) Evaluation of CSF kappa free light chains for the diagnosis of multiple sclerosis (MS): a comparison with oligoclonal bands (OCB) detection via isoelectric focusing (IEF) coupled with immunoblotting. J Clin Pathol 76:353\u2013356. https:\/\/doi.org\/10.1136\/jcp-2022-208354","journal-title":"J Clin Pathol"},{"key":"12907_CR96","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2016.160930","author":"I Crespi","year":"2017","unstructured":"Crespi I, Sulas M, Mora R et al (2017) Combined use of Kappa free light chain index and isoelectrofocusing of cerebro-spinal fluid in diagnosing multiple sclerosis: performances and costs. Clin Lab. https:\/\/doi.org\/10.7754\/Clin.Lab.2016.160930","journal-title":"Clin Lab"},{"key":"12907_CR97","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3390\/medicina55060245","volume":"55","author":"B Lo Sasso","year":"2019","unstructured":"Lo Sasso B, Agnello L, Bivona G et al (2019) Cerebrospinal fluid analysis in multiple sclerosis diagnosis: an update. Medicina (B Aires) 55:245. https:\/\/doi.org\/10.3390\/medicina55060245","journal-title":"Medicina (B Aires)"},{"key":"12907_CR98","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cca.2019.07.027","volume":"497","author":"H Reiber","year":"2019","unstructured":"Reiber H, Zeman D, Ku\u0161nierov\u00e1 P et al (2019) Diagnostic relevance of free light chains in cerebrospinal fluid: the hyperbolic reference range for reliable data interpretation in quotient diagrams. Clin Chim Acta 497:153\u2013162. https:\/\/doi.org\/10.1016\/j.cca.2019.07.027","journal-title":"Clin Chim Acta"},{"key":"12907_CR99","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/13524585221134213","volume":"29","author":"H Hegen","year":"2023","unstructured":"Hegen H, Walde J, Berek K et al (2023) Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a systematic review and meta-analysis. Mult Scler J 29:169\u2013181. https:\/\/doi.org\/10.1177\/13524585221134213","journal-title":"Mult Scler J"},{"key":"12907_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1327947","author":"H Hegen","year":"2023","unstructured":"Hegen H, Berek K, Cavalla P et al (2023) Diagnostic value of kappa free light chain index in patients with primary progressive multiple sclerosis a multicentre study. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1327947","journal-title":"Front Immunol"},{"key":"12907_CR101","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac220","author":"G Arrambide","year":"2022","unstructured":"Arrambide G, Espejo C, Carbonell-Mirabent P et al (2022) The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteria. Brain. https:\/\/doi.org\/10.1093\/brain\/awac220","journal-title":"Brain"},{"key":"12907_CR102","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000200049","volume":"10","author":"M Levraut","year":"2023","unstructured":"Levraut M, Laurent-Chabalier S, Ayrignac X et al (2023) Kappa free light chain biomarkers are efficient for the diagnosis of multiple sclerosis: a large multicenter cohort study. Neurol Neuroimmunol Neuroinflamm 10:1\u201314. https:\/\/doi.org\/10.1212\/NXI.0000000000200049","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12907_CR103","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1177\/13524585221134217","volume":"29","author":"H Hegen","year":"2023","unstructured":"Hegen H, Arrambide G, Gnanapavan S et al (2023) Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: a consensus statement. Mult Scler J 29:182\u2013195. https:\/\/doi.org\/10.1177\/13524585221134217","journal-title":"Mult Scler J"},{"key":"12907_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14121","author":"D Ferraro","year":"2019","unstructured":"Ferraro D, Trovati A, Bedin R et al (2019) Cerebrospinal fluid free light kappa and lambda chains in oligoclonal band-negative patients with suspected Multiple Sclerosis. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.14121","journal-title":"Eur J Neurol"},{"key":"12907_CR105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2019.577122","volume":"339","author":"P Cavalla","year":"2020","unstructured":"Cavalla P, Caropreso P, Limoncelli S et al (2020) Kappa free light chains index in the differential diagnosis of Multiple Sclerosis from Neuromyelitis optica spectrum disorders and other immune-mediated central nervous system disorders. J Neuroimmunol 339:577122. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.577122","journal-title":"J Neuroimmunol"},{"key":"12907_CR106","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1177\/13524585211064121","volume":"28","author":"G Bernardi","year":"2022","unstructured":"Bernardi G, Biagioli T, Malpassi P et al (2022) The contribute of cerebrospinal fluid free light-chain assay in the diagnosis of multiple sclerosis and other neurological diseases in an Italian multicenter study. Mult Scler J 28:1364\u20131372. https:\/\/doi.org\/10.1177\/13524585211064121","journal-title":"Mult Scler J"},{"key":"12907_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10100856","author":"D Ferraro","year":"2020","unstructured":"Ferraro D, Bedin R, Natali P et al (2020) Kappa index versus CSF oligoclonal bands in predicting multiple sclerosis and infectious\/inflammatory CNS disorders. Diagnostics Basel. https:\/\/doi.org\/10.3390\/diagnostics10100856","journal-title":"Diagnostics Basel"},{"key":"12907_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104573","volume":"91","author":"H Hegen","year":"2023","unstructured":"Hegen H, Berek K, Bsteh G et al (2023) Articles Kappa free light chain and neuro fi lament light independently predict early multiple sclerosis disease activity: a cohort study. EBioMedicine 91:104573. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104573","journal-title":"EBioMedicine"},{"key":"12907_CR109","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1007\/s00415-023-11817-9","volume":"270","author":"I Rosenstein","year":"2023","unstructured":"Rosenstein I, Axelsson M, Novakova L et al (2023) Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing\u2013remitting multiple sclerosis. J Neurol 270:4800\u20134811. https:\/\/doi.org\/10.1007\/s00415-023-11817-9","journal-title":"J Neurol"},{"key":"12907_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/NXI.0000000000001005","volume":"8","author":"K Berek","year":"2021","unstructured":"Berek K, Bsteh G, Auer M et al (2021) Kappa-free light chains in CSF predict early multiple sclerosis disease activity. Neurol Neuroimmunol Neuroinflamm 8:1\u201310. https:\/\/doi.org\/10.1212\/NXI.0000000000001005","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12907_CR111","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200156","author":"M Levraut","year":"2023","unstructured":"Levraut M, Gavoille A, Landes Chateau C et al (2023) Kappa free light chain index predicts disease course in clinically and radiologically isolated syndromes. Neurol Neuroimmunol Neuroinflamm. https:\/\/doi.org\/10.1212\/NXI.0000000000200156","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12907_CR112","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1106028","author":"I Rosenstein","year":"2023","unstructured":"Rosenstein I, Axelsson M, Novakova L et al (2023) High levels of kappa free light chain synthesis predict cognitive decline in relapsing-remitting multiple sclerosis. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2023.1106028","journal-title":"Front Immunol"},{"key":"12907_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105548","volume":"85","author":"L Gaetani","year":"2024","unstructured":"Gaetani L, Salvadori N, Brachelente G et al (2024) Intrathecal B cell activation and memory impairment in multiple sclerosis. Mult Scler Relat Disord 85:105548. https:\/\/doi.org\/10.1016\/j.msard.2024.105548","journal-title":"Mult Scler Relat Disord"},{"key":"12907_CR114","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12987-021-00272-1","volume":"18","author":"C Harrer","year":"2021","unstructured":"Harrer C, Otto F, Pilz G et al (2021) The CXCL13\/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF. Fluids Barriers CNS 18:40. https:\/\/doi.org\/10.1186\/s12987-021-00272-1","journal-title":"Fluids Barriers CNS"},{"key":"12907_CR115","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12987-020-0170-5","volume":"17","author":"G Pilz","year":"2020","unstructured":"Pilz G, Sakic I, Wipfler P et al (2020) Chemokine CXCL13 in serum, CSF and blood\u2013CSF barrier function: evidence of compartment restriction. Fluids Barriers CNS 17:7. https:\/\/doi.org\/10.1186\/s12987-020-0170-5","journal-title":"Fluids Barriers CNS"},{"key":"12907_CR116","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3390\/biomedicines10092099","volume":"10","author":"A Pachner","year":"2022","unstructured":"Pachner A (2022) The brave new world of early treatment of multiple sclerosis: using the molecular biomarkers CXCL13 and neurofilament light to optimize immunotherapy. Biomedicines 10:2099. https:\/\/doi.org\/10.3390\/biomedicines10092099","journal-title":"Biomedicines"},{"key":"12907_CR117","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000520","volume":"6","author":"AR Pachner","year":"2019","unstructured":"Pachner AR, DiSano K, Royce DB, Gilli F (2019) Clinical utility of a molecular signature in inflammatory demyelinating disease. Neurol Neuroimmunol Neuroinflamm 6:e520. https:\/\/doi.org\/10.1212\/NXI.0000000000000520","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12907_CR118","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1212\/WNL.0b013e3181c5b457","volume":"73","author":"F Sellebjerg","year":"2009","unstructured":"Sellebjerg F, Bornsen L, Khademi M et al (2009) Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. Neurology 73:2003\u20132010. https:\/\/doi.org\/10.1212\/WNL.0b013e3181c5b457","journal-title":"Neurology"},{"key":"12907_CR119","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1177\/1352458512473362","volume":"19","author":"E Alvarez","year":"2013","unstructured":"Alvarez E, Piccio L, Mikesell RJ et al (2013) CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions. Mult Scler J 19:1204\u20131208. https:\/\/doi.org\/10.1177\/1352458512473362","journal-title":"Mult Scler J"},{"key":"12907_CR120","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/01.wnl.0000171349.06645.79","volume":"65","author":"TA Rupprecht","year":"2005","unstructured":"Rupprecht TA, Pfister HW, Angele B et al (2005) The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 65:448\u2013450. https:\/\/doi.org\/10.1212\/01.wnl.0000171349.06645.79","journal-title":"Neurology"},{"key":"12907_CR121","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1352458510389102","volume":"17","author":"M Khademi","year":"2011","unstructured":"Khademi M, Kockum I, Andersson ML et al (2011) Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler J 17:335\u2013343. https:\/\/doi.org\/10.1177\/1352458510389102","journal-title":"Mult Scler J"},{"key":"12907_CR122","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jneuroim.2015.04.011","volume":"283","author":"D Ferraro","year":"2015","unstructured":"Ferraro D, Galli V, Vitetta F et al (2015) Cerebrospinal fluid CXCL13 in clinically isolated syndrome patients: association with oligoclonal IgM bands and prediction of multiple sclerosis diagnosis. J Neuroimmunol 283:64\u201369. https:\/\/doi.org\/10.1016\/j.jneuroim.2015.04.011","journal-title":"J Neuroimmunol"},{"key":"12907_CR123","doi-asserted-by":"publisher","first-page":"205521732098139","DOI":"10.1177\/2055217320981396","volume":"6","author":"KD DiSano","year":"2020","unstructured":"DiSano KD, Gilli F, Pachner AR (2020) Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis. Mult Scler J Exp Transl Clin 6:205521732098139. https:\/\/doi.org\/10.1177\/2055217320981396","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"12907_CR124","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1084\/jem.189.11.1747","volume":"189","author":"P Schneider","year":"1999","unstructured":"Schneider P, MacKay F, Steiner V et al (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747\u20131756. https:\/\/doi.org\/10.1084\/jem.189.11.1747","journal-title":"J Exp Med"},{"key":"12907_CR125","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14728222.2020.1821647","volume":"24","author":"R Magliozzi","year":"2020","unstructured":"Magliozzi R, Marastoni D, Calabrese M (2020) The BAFF \/ APRIL system as therapeutic target in multiple sclerosis. Expert Opin Ther Targets 24:1135\u20131145. https:\/\/doi.org\/10.1080\/14728222.2020.1821647","journal-title":"Expert Opin Ther Targets"},{"key":"12907_CR126","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1056\/NEJMoa1610528","volume":"376","author":"M Steri","year":"2017","unstructured":"Steri M, Orr\u00f9 V, Idda ML et al (2017) Overexpression of the Cytokine BAFF and autoimmunity risk. N Engl J Med 376:1615\u20131626. https:\/\/doi.org\/10.1056\/NEJMoa1610528","journal-title":"N Engl J Med"},{"key":"12907_CR127","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1084\/jem.20041674","volume":"201","author":"M Krumbholz","year":"2005","unstructured":"Krumbholz M, Theil D, Derfuss T et al (2005) BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 201:195\u2013200. https:\/\/doi.org\/10.1084\/jem.20041674","journal-title":"J Exp Med"},{"key":"12907_CR128","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.clim.2017.10.009","volume":"187","author":"Y Miyazaki","year":"2018","unstructured":"Miyazaki Y, Niino M, Takahashi E et al (2018) Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis. Clin Immunol 187:95\u2013101. https:\/\/doi.org\/10.1016\/j.clim.2017.10.009","journal-title":"Clin Immunol"},{"key":"12907_CR129","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"SAJ Thompson","year":"2010","unstructured":"Thompson SAJ, Jones JL, Cox AL et al (2010) B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol 30:99\u2013105. https:\/\/doi.org\/10.1007\/s10875-009-9327-3","journal-title":"J Clin Immunol"},{"key":"12907_CR130","doi-asserted-by":"publisher","first-page":"5021","DOI":"10.3390\/ijms21145021","volume":"21","author":"J Traub","year":"2020","unstructured":"Traub J, H\u00e4usser-Kinzel S, Weber M (2020) Differential effects of MS therapeutics on B cells\u2014implications for their use and failure in AQP4-positive NMOSD patients. Int J Mol Sci 21:5021. https:\/\/doi.org\/10.3390\/ijms21145021","journal-title":"Int J Mol Sci"},{"key":"12907_CR131","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S1474-4422(14)70028-6","volume":"13","author":"L Kappos","year":"2014","unstructured":"Kappos L, Hartung H-P, Freedman MS et al (2014) Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol 13:353\u2013363. https:\/\/doi.org\/10.1016\/S1474-4422(14)70028-6","journal-title":"Lancet Neurol"},{"key":"12907_CR132","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker D, Marta M, Pryce G et al (2017) Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16:41\u201350. https:\/\/doi.org\/10.1016\/j.ebiom.2017.01.042","journal-title":"EBioMedicine"},{"key":"12907_CR133","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jneuroim.2010.01.011","volume":"220","author":"F Piazza","year":"2010","unstructured":"Piazza F, DiFrancesco JC, Fusco ML et al (2010) Cerebrospinal fluid levels of BAFF and APRIL in untreated multiple sclerosis. J Neuroimmunol 220:104\u2013107. https:\/\/doi.org\/10.1016\/j.jneuroim.2010.01.011","journal-title":"J Neuroimmunol"},{"key":"12907_CR134","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1177\/1352458511398887","volume":"17","author":"S Ragheb","year":"2011","unstructured":"Ragheb S, Li Y, Simon K et al (2011) Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid. Mult Scler J 17:819\u2013829. https:\/\/doi.org\/10.1177\/1352458511398887","journal-title":"Mult Scler J"},{"key":"12907_CR135","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10875-012-9709-9","volume":"32","author":"H Wang","year":"2012","unstructured":"Wang H, Wang K, Zhong X et al (2012) Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J Clin Immunol 32:1007\u20131011. https:\/\/doi.org\/10.1007\/s10875-012-9709-9","journal-title":"J Clin Immunol"},{"key":"12907_CR136","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149411","volume":"11","author":"K Kothur","year":"2016","unstructured":"Kothur K, Wienholt L, Tantsis EM et al (2016) B Cell, Th17, and neutrophil related cerebrospinal fluid cytokine\/chemokines are elevated in MOG antibody associated demyelination. PLoS ONE 11:e0149411. https:\/\/doi.org\/10.1371\/journal.pone.0149411","journal-title":"PLoS ONE"},{"key":"12907_CR137","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jneuroim.2016.05.013","volume":"297","author":"M Puthenparampil","year":"2016","unstructured":"Puthenparampil M, Miante S, Federle L et al (2016) BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset. J Neuroimmunol 297:63\u201367. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.05.013","journal-title":"J Neuroimmunol"},{"key":"12907_CR138","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.it.2018.07.002","volume":"39","author":"E Meinl","year":"2018","unstructured":"Meinl E, Thaler FS, Lichtenthaler SF (2018) Shedding of BAFF\/APRIL receptors controls B cells. Trends Immunol 39:673\u2013676. https:\/\/doi.org\/10.1016\/j.it.2018.07.002","journal-title":"Trends Immunol"},{"key":"12907_CR139","doi-asserted-by":"publisher","first-page":"542","DOI":"10.4049\/jimmunol.1402070","volume":"194","author":"FS Hoffmann","year":"2015","unstructured":"Hoffmann FS, Kuhn P-H, Laurent SA et al (2015) The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol 194:542\u2013552. https:\/\/doi.org\/10.4049\/jimmunol.1402070","journal-title":"J Immunol"},{"key":"12907_CR140","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12974-015-0450-1","volume":"12","author":"M Wuhrer","year":"2015","unstructured":"Wuhrer M, Selman MHJ, McDonnell LA et al (2015) Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation 12:235. https:\/\/doi.org\/10.1186\/s12974-015-0450-1","journal-title":"J Neuroinflammation"},{"key":"12907_CR141","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/pmic.200800715","volume":"9","author":"C Huhn","year":"2009","unstructured":"Huhn C, Selman MHJ, Ruhaak LR et al (2009) IgG glycosylation analysis. Proteomics 9:882\u2013913. https:\/\/doi.org\/10.1002\/pmic.200800715","journal-title":"Proteomics"},{"key":"12907_CR142","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1177\/1352458516631036","volume":"22","author":"Y Decker","year":"2016","unstructured":"Decker Y, Schomburg R, N\u00e9meth E et al (2016) Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients. Mult Scler J 22:1794\u20131803. https:\/\/doi.org\/10.1177\/1352458516631036","journal-title":"Mult Scler J"},{"key":"12907_CR143","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0095192","volume":"9","author":"E Assarsson","year":"2014","unstructured":"Assarsson E, Lundberg M, Holmquist G et al (2014) Homogenous 96-Plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9:e95192. https:\/\/doi.org\/10.1371\/journal.pone.0095192","journal-title":"PLoS ONE"},{"key":"12907_CR144","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2023.100629","volume":"22","author":"CE Teunissen","year":"2023","unstructured":"Teunissen CE, Kimble L, Bayoumy S et al (2023) Methods to discover and validate biofluid-based biomarkers in neurodegenerative dementias. Mol Cell Proteomics 22:100629. https:\/\/doi.org\/10.1016\/j.mcpro.2023.100629","journal-title":"Mol Cell Proteomics"},{"key":"12907_CR145","doi-asserted-by":"publisher","first-page":"6903","DOI":"10.1038\/s41467-023-42682-9","volume":"14","author":"J \u00c5kesson","year":"2023","unstructured":"\u00c5kesson J, Hojjati S, Hellberg S et al (2023) Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis. Nat Commun 14:6903. https:\/\/doi.org\/10.1038\/s41467-023-42682-9","journal-title":"Nat Commun"},{"key":"12907_CR146","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/ana.25083","volume":"82","author":"C Barbour","year":"2017","unstructured":"Barbour C, Kosa P, Komori M et al (2017) Molecular-based diagnosis of multiple sclerosis and its progressive stage. Ann Neurol 82:795\u2013812. https:\/\/doi.org\/10.1002\/ana.25083","journal-title":"Ann Neurol"},{"key":"12907_CR147","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/nrneurol.2015.173","volume":"11","author":"CE Teunissen","year":"2015","unstructured":"Teunissen CE, Malekzadeh A, Leurs C et al (2015) Body fluid biomarkers for multiple sclerosis\u2014the long road to clinical application. Nat Rev Neurol 11:585\u2013596. https:\/\/doi.org\/10.1038\/nrneurol.2015.173","journal-title":"Nat Rev Neurol"},{"key":"12907_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101009","volume":"44","author":"M Di Filippo","year":"2024","unstructured":"Di Filippo M, Gaetani L, Centonze D et al (2024) Fluid biomarkers in multiple sclerosis: from current to future applications. Lancet Regional Health Europe 44:101009. https:\/\/doi.org\/10.1016\/j.lanepe.2024.101009","journal-title":"Lancet Regional Health Europe"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12907-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12907-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12907-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:40:39Z","timestamp":1742218839000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12907-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":148,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12907"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12907-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EDS received travel grants and\/or speaker honoraria from Alexion, Almirall, Biogen, Bristol-Myers Squibb, Horizon, Novartis, Roche, Sanofi, and Viatris. DF has received travel grants and\/or fees for speaking and\/or advisory boards from Alexion, Binding Site, Biogen, Bristol-Myers Squibb, Celgene, Merck, Novartis, Roche, and Sanofi. EE received travel grants from Biogen and Janssen. LG participated on advisory boards for, and received speaker or writing honoraria and travel grants from Almirall, Biogen, Euroimmun, Fujirebio, Lilly, Merck, Mylan, Novartis, Roche, Sanofi, Siemens Healthineers, and Teva. MDF participated on advisory boards and steering committees for and received speaker or writing honoraria, research support and funding for travelling from Alexion, Amgen, BMS, Bayer, Biogen Idec, Genzyme, Horizon, Janssen, Merck, Mylan, Novartis, Roche, Siemens Healthineers, Teva and Viatris. LP reports no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"211"}}